文献速递产科母胎医学生殖医学

母亲多囊卵巢综合征与糖尿病对早产及子代出生体型的关联:一项基于人群的队列研究

Association of maternal polycystic ovary syndrome and diabetes with preterm birth and offspring birth size: a population-based cohort study.
PubMed 文献 · Hum Reprod · 2022-01-01

该基于芬兰1996至2014年全部活产的队列研究纳入1 097 753名儿童,分析母亲多囊卵巢综合征(PCOS)与不同类型糖尿病对早产及子代出生体型的关联。结果显示,在非胰岛素治疗的2型糖尿病和妊娠期糖尿病(GDM)母亲中,PCOS与总早产和自发性早产风险升高相关;在胰岛素治疗糖尿病母亲中,PCOS与子代大于胎龄儿(LGA)风险降低相关。

要点

  • 非胰岛素治疗2型糖尿病母亲中,PCOS者总早产OR 2.84、自发性早产OR 4.02,均高于无PCOS者。
  • GDM母亲中,PCOS者总早产OR 1.42、自发性早产OR 1.80,均高于无PCOS者。
  • 胰岛素治疗糖尿病母亲中,PCOS者子代LGA风险低于无PCOS者(OR 18.90 vs 32.04)。

核心结论

  • PCOS的存在意味着非胰岛素治疗的2型糖尿病和GDM母亲的总早产和自发性早产风险更高,以及胰岛素治疗糖尿病母亲的子代LGA风险更低。
  • PCOS增加的早产风险在非胰岛素治疗的2型糖尿病中可由孕前BMI解释或部分由不孕治疗和子痫前期解释,但在GDM中不能。

研究设计与样本

  • 这是一项基于人群的队列研究,纳入芬兰1996年至2014年间所有活产,排除同时有可导致类似PCOS症状和体征的母亲诊断的儿童,共纳入1 097 753名儿童。
  • 通过链接国家登记数据库识别母亲PCOS的出生(n=24 682),并按糖尿病类型分层。
  • 使用逻辑回归分析母亲PCOS与合并胰岛素治疗糖尿病、非胰岛素治疗2型糖尿病或GDM与子代LGA和小于胎龄儿(SGA)的关联。
  • 使用广义估计方程评估母亲PCOS和糖尿病与早产风险的关系,并在加法和乘法尺度上评估PCOS与糖尿病之间的潜在交互作用。

主要发现

  • 以无PCOS且无糖尿病的母亲为参照并调整母亲和出生因素后,非胰岛素治疗2型糖尿病母亲中,有PCOS者总早产风险OR 2.84(95%CI 2.21-3.66),无PCOS者OR 1.91(95%CI 1.77-2.07),P=0.01;有PCOS者自发性早产风险OR 4.02(95%CI 2.94-5.50),无PCOS者OR 2.35(95%CI 2.13-2.59),P=0.001。
  • GDM母亲中,有PCOS者总早产风险OR 1.42(95%CI 1.27-1.58),无PCOS者OR 0.89(95%CI 0.86-0.91),P=0.0001;有PCOS者自发性早产风险OR 1.80(95%CI 1.59-2.05),无PCOS者OR 1.01(95%CI 0.98-1.05),P=0.0001。
  • 在2型糖尿病母亲中,进一步调整母亲BMI后,有和无PCOS者之间的早产风险差异消失;调整不孕治疗和子痫前期也显著降低了PCOS相关的早产风险。
  • 在GDM母亲中,进行上述调整或分层分析后,有PCOS者的总早产和自发性早产风险仍较高。
  • 胰岛素治疗糖尿病母亲中,有PCOS者子代LGA风险OR 18.90(95%CI 14.21-25.14),无PCOS者OR 32.04(95%CI 29.79-34.46),P=0.0001,偏离加法尺度(相对超额风险交互作用-11.74,95%CI -16.17至-7.31,P<0.001)和乘法尺度(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究中基于登记数据库的诊断仅捕获寻求医疗照护且有活产的PCOS女性。
  • 将无排卵相关的女性不孕作为PCOS暴露存在错误分类的风险。
  • 孕前糖尿病的样本量小。
  • 分析中未考虑无糖尿病诊断的孕妇在孕期购买胰岛素的情况。
  • 对于接受胰岛素或其他药物治疗的患者,无法评估其用药依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is the presence of polycystic ovary syndrome (PCOS) associated with more adverse infant outcomes in mothers with different types of diabetes? SUMMARY ANSWER: The presence of PCOS implies higher risks of total (medically indicated and spontaneously combined) and spontaneous preterm birth in mothers with non-insulin-treated type 2 diabetes and gestational diabetes mellitus (GDM), and lower risk of offspring being large for gestational age (LGA) in mothers with insulin-treated diabetes. WHAT IS KNOWN ALREADY: PCOS is suggested to be an independent risk factor for adverse infant outcomes, and it is highly prevalent in mothers with diabetes. However, the impact of PCOS on the associations of different types of maternal diabetes with preterm birth and offspring birth sizes has not been reported. STUDY DESIGN, SIZE, DURATION: This is a population-based cohort study including all live births between 1996 and 2014 in Finland. Children with concurrent maternal diagnoses that could cause signs and symptoms similar to PCOS were excluded. A total of 1 097 753 children were included. PARTICIPANTS/MATERIALS, SETTING, METHODS: National registries were linked to identify births with maternal PCOS (n = 24 682), stratified by diabetes types. Logistic regression was used to examine the association of maternal PCOS and comorbid insulin-treated diabetes, non-insulin-treated type 2 diabetes or GDM with offspring LGA and small for gestational age (SGA). Generalized estimating equation was used to assess the risk of preterm birth in relation to maternal PCOS and diabetes. Potential interaction between PCOS and diabetes was evaluated on both additive and multiplicative scales. MAIN RESULTS AND THE ROLE OF CHANCE: Using mothers with no PCOS and no diabetes as the reference and adjusting for maternal and birth factors, there were higher risks of total (odds ratio (OR) 2.84, 95% CI 2.21 - 3.66 vs. OR 1.91, 95% CI 1.77 - 2.07, P = 0.01) and spontaneous (OR 4.02, 95% CI 2.94 - 5.50 vs. OR 2.35, 95% CI 2.13 - 2.59, P = 0.001) preterm birth for those with PCOS in mothers with non-insulin-treated type 2 diabetes and higher risks of total (OR 1.42, 95% CI 1.27-1.58 vs. OR 0.89, 95% CI 0.86-0.91, P = 0.0001) and spontaneous (OR 1.80, 95% CI 1.59-2.05 vs. OR 1.01, 95% CI 0.98-1.05, P = 0.0001) preterm birth for those with PCOS in mothers with GDM. Among mothers with type 2 diabetes, further adjusting for maternal BMI eliminated the difference in preterm birth risks between those with and those without PCOS, and adjustment for infertility treatment and pre-eclampsia also reduced the preterm risks associated with PCOS significantly. For mothers with GDM, however, the risks of total and spontaneous preterm birth remained higher for those with PCOS following these aforementioned adjustments or stratified analysis. The risk of offspring being LGA was lower for those with PCOS than those without PCOS among mothers with insulin-treated diabetes (OR 18.90, 95% CI 14.21-25.14 vs. OR 32.04, 95% CI 29.79-34.46, P = 0.0001), showing departure from additivity (relative excess risk due to interaction -11.74, 95% CI -16.17 to -7.31, P < 0.001) and multiplicativity (P < 0.001). PCOS did not alter the risk estimate of preterm birth in mothers with insulin-treated diabetes or offspring LGA and SGA in mothers with type 2 diabetes or GDM. LIMITATIONS, REASONS FOR CAUTION: The register-based diagnoses used in this study captured only women with PCOS seeking medical care and having live births. Including female infertility associated with anovulation as PCOS exposure was a risk for misclassification. Sample sizes for pregestational diabetes were small. Insulin purchase during pregnancy in those without a diabetes diagnosis was not accounted for in the analysis. For patients treated with insulin or other medications, we were unable to assess how they complied with such prescriptions. Also, maternal BMI was recorded only once in early pregnancy, thus the potential influence of gestational weight gain on birth outcomes could not be examined. Data on the causes for preterm birth were not available from the registers. WIDER IMPLICATIONS OF THE FINDINGS: The presence of PCOS implied higher risks of total and spontaneous preterm birth in mothers with type 2 diabetes or GDM, and lower risk of offspring being LGA in mothers with insulin-treated diabetes. The higher risks of preterm birth added by PCOS could be explained by prepregnancy BMI or in part by infertility treatment and pre-eclampsia in maternal non-insulin-treated type 2 diabetes, but not in maternal GDM. The differential effects of PCOS on the associations of different types of maternal diabetes with infant outcomes have implications for preventative strategies and clinical counseling for affected pregnancies. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by Shandong Provincial Natural Science Foundation, China (ZR2020MH064 to X.C.), Shandong Province Medical and Health Technology Development Plan (2018WS338 to X.C.), the joint research funding of Shandong University and Karolinska Institute (SDU-KI-2019-08 to X.C. and C.L.), the Finnish National Institute for Health and Welfare: Drug and pregnancy project (M.G.), the Swedish Research Council (2014-10171 to C.L.), the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institute Stockholm County Council (SLL20170292 and SLL20190589 to C.L.), the Swedish Brain Foundation (FO2019-0201 and FO2020-0305 to C.L.). X.C. received grants from the China Scholarship Council at the beginning of the study. The authors have no competing interests to disclose. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Chen X, Gissler M, Lavebratt C, et al. Association of maternal polycystic ovary syndrome and diabetes with preterm birth and offspring birth size: a population-based cohort study. Hum Reprod. 2022. PMID: 35348682. doi:10.1093/humrep/deac050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。